Amgen Names James Bradner Chief Scientific Officer
14 Décembre 2023 - 3:53PM
Dow Jones News
By Colin Kellaher
Amgen has hired James Bradner as executive vice president of
research and development and chief scientific officer of the
biotechnology company.
Amgen on Thursday said Bradner has been a clinician at the
Dana-Farber Cancer Institute for the past year after a stint as
president of the Novartis Institutes for BioMedical Research, where
he was a member of the executive committee of Swiss drugmaker
Novartis.
Amgen said Bradner succeeds David Reese, who is taking on the
newly created post of executive vice president and chief technology
officer, and will be responsible for accelerating the use of
technology and artificial intelligence across all facets of the
Thousand Oaks, Calif., company.
Bradner, meanwhile, will be responsible for advancing Amgen's
pipeline and its worldwide research efforts.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 14, 2023 09:38 ET (14:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Amgen (NASDAQ:AMGN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
